Business
Indivior Announces Completion of Redomiciliation to the United States
RICHMOND, Va., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced completion of its redomiciliation from the
About this update from Indivior Pharmaceuticals, Inc.
[{"type":"text","content":"RICHMOND, Va., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced completion of its redomiciliation from the United Kingdom to the United States. As a result, Indivior Pharmaceuticals, Inc., a new Delaware corporation (“IPI”), has become the new parent company. Indivior PLC is renamed Indivior Ltd. and has become a wholly-owned subsidiary of IPI. The common stock of Indivior Pharmaceuticals, Inc., is listed on Nasdaq and will continue to trade under the symbol “INDV.”The last day of trading Indivior PLC ordinary shares on Nasdaq was January 23, 2026. Shareholders of Indivior PLC received one new IPI common share for each Indivior PLC ordinary share held as of the scheme record date. The redomiciliation was approved by Indivior shareholders at an extraordinary general meeting (EGM) on December 11, 2025. Indivior believes the change in domicile will expand the benefits of its U.S. stock listing, including: Strengthening Indivior’s U.S. capital markets presenceIncreasing potential U.S. equity indexationSimplifying corporate governance and reducing complexityFurther positioning Indivior as a U.S. based treatment innovator, enabling closer collaboration with public health leaders on advancing SUBLOCADE® for opioid use disorder IPI is subject to the reporting requirements of the U.S. Securities and Exchange Commission (“SEC”) as a domestic issuer and applicable exchange rules of Nasdaq. Further details regarding the redomiciliation can be found in an 8-K filing made today with the SEC. Important Cautionary Note Regarding Forward-looking Statements Certain statements contained herein are forward-looking statements. Forward-looking statements include, among other things, express and implied statements pertaining to (i) our expectations regarding expected benefits of redomiciliation, (ii) potential inclusion in additional U.S. equity indices, (iii) expected simplified corporate governance and reduced complexity, (iv) expected improved positioning as a U.S.-based treatment innovator and potential closer collaboration with public health leaders on advancing SUBLOCADE® for opioid use disorder, and (v) statements containing the words \"believe,\" \"anticipate,” \"plan,” \"expect,” \"intend,” \"estimate,” \"forecast,\" \"strategy,” \"target,” \"guidance,” \"outlook,” \"potential,” \"project,” \"pr...